SCHEDULE: CytoMed Therapeutics Shareholder Discloses Stake

Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Ltd, has amended his Schedule 13D filing to report beneficial ownership of 2,899,746 Ordinary Shares, representing 24.30% of the company's outstanding stock.

Summary

• Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Ltd, has updated his Schedule 13D filing.
• He now beneficially owns 2,899,746 Ordinary Shares, which constitutes 24.30% of the company's outstanding shares.
• This ownership includes shares held indirectly through Glorious Finance Limited (55% stake), shares held by EP Capital Inc., and shares held directly.
• Recent acquisitions include 200,000 Ordinary Shares purchased on July 14 and July 20, 2026, from Teoh Teik Kee at $1.50 per share.
• These purchases were funded by personal funds through a brokerage account.
• Mr. Kong has sole voting and dispositive power over 824,436 shares and shared power over 3,773,291 shares.
• He states no current intention or plan for actions beyond his role as Chairman and Director, except as may be discussed or voted upon.
• There is a potential for a 'group' to be deemed acting with other shareholders of Glorious Finance Limited due to shared voting and dispositive power, though no formal agreement exists.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant and disclosed stake by a key executive, with no immediate negative implications but also no explicit positive catalysts beyond insider confidence.

Positives

• Significant beneficial ownership of 24.30% by a key executive (Chairman and Director) indicates strong alignment with company performance.
• Recent share purchases by the Chairman demonstrate personal investment and confidence in the company.
• The Chairman has sole voting and dispositive power over a substantial portion of his holdings, allowing for decisive action.
• The filing clarifies the structure of ownership, including indirect holdings through Glorious Finance Limited and EP Capital Inc.

Negatives

• The potential for a 'group' to be deemed acting with other Glorious Finance Limited shareholders, despite the absence of a formal agreement, could lead to scrutiny.
• The filing does not provide specific details on the capital contributions made for shares held indirectly or by EP Capital Inc., only that they were in exchange for capital contributions.

Risks

• The absence of a formal agreement among shareholders of Glorious Finance Limited regarding voting or investment decisions could lead to future disagreements or uncertainty.
• While no current plans are disclosed, the Chairman's significant stake and role mean his future intentions regarding strategic decisions could impact the company.

Future Outlook

Choo Chee Kong has no current intention, plan, or proposal with respect to matters such as acquiring additional securities, disposing of securities, changing the issuer's business or management, material changes to the issuer's capitalization or dividend policy, or other extraordinary corporate transactions, except as may arise in his capacity as Chairman and Director and be subject to discussion or vote.

Management Comments

• "The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others."
• "Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D."

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for understanding significant ownership changes and potential shifts in control or influence within publicly traded companies. This filing by a key executive of CytoMed Therapeutics Ltd provides insight into insider confidence and ownership structure.

Stakeholder Impact

• Shareholders: The filing confirms a substantial stake by the Chairman, potentially indicating stability or a strong alignment of interests. However, the lack of formal agreements among Glorious Finance shareholders could introduce future uncertainty.
• Management: The Chairman's disclosed ownership and voting power reinforce his influence on corporate decisions.
• Creditors: No direct impact is indicated, but significant ownership by management can sometimes correlate with a more stable financial outlook.

Next Steps

• Choo Chee Kong may vote on or discuss matters related to items (a) through (j) of Item 4 of Schedule 13D with representatives of the Issuer and others in his capacity as Chairman and Director.

Key Dates

Recommendation

The filing primarily serves as a disclosure of existing beneficial ownership and recent transactions by a key executive. While the significant stake and directorship are positive indicators of alignment, there are no new strategic initiatives, financial performance updates, or forward-looking statements that would strongly warrant a buy or sell recommendation at this time. A 'hold' reflects the current information's neutral impact on immediate investment decisions.

Keywords

CytoMed Therapeutics, Schedule 13D, Beneficial Ownership, Ordinary Shares, Choo Chee Kong, Glorious Finance Limited, EP Capital Inc., Share Purchase Agreement